Triglav Investments D.O.O. Decreases Stock Holdings in CVS Health Corporation $CVS

Key Points

• Triglav Investments D.O.O. cut its CVS Health stake by 22.3% in the fourth quarter, selling 33,200 shares and ending with 115,950 shares valued at about $9.2 million.
• Insider selling has been notable, including large transactions by EVP Tilak Mandadi and Director Larry Robbins; insiders sold 3.44 million shares worth roughly $323.7 million over the last three months.
• CVS Health posted solid fundamentals and upbeat analyst sentiment, beating earnings and revenue estimates in its latest quarter, while analysts largely maintain Buy/Outperform ratings with an average price target of $98.88.

Triglav Investments D.O.O. lessened its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 22.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 115,950 shares of the pharmacy operator's stock after selling 33,200 shares during the period. Triglav Investments D.O.O.'s holdings in CVS Health were worth $9,202,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd raised its position in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after buying an additional 281 shares during the last quarter. Ares Financial Consulting LLC acquired a new position in CVS Health during the fourth quarter worth approximately $29,000. Dogwood Wealth Management LLC increased its position in CVS Health by 93.7% during the fourth quarter. Dogwood Wealth Management LLC now owns 370 shares of the pharmacy operator's stock worth $29,000 after purchasing an additional 179 shares during the last quarter. GoalVest Advisory LLC acquired a new position in CVS Health during the fourth quarter worth approximately $32,000. Finally, MidAtlantic Capital Management Inc. acquired a new position in CVS Health during the fourth quarter worth approximately $35,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

Insider Buying and Selling

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares of the company's stock, valued at $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the completion of the sale, the director directly owned 4,824,799 shares of the company's stock, valued at $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last three months. 0.85% of the stock is owned by insiders.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS Caremark said it will restore coverage of Eli Lilly’s Zepbound and add Lilly’s new obesity pill to its standard drug plans, a move that could boost CVS’s pharmacy-benefit relevance and improve customer access to GLP-1 medications. CVS brings back coverage for Lilly's obesity drug Zepbound
• Positive Sentiment: The company announced expanded GLP-1 coverage options, which management framed as improving affordability and access while supporting more sustainable long-term coverage. CVS Caremark Delivers Affordability and Access to GLP-1 Weight Management Medications with Expanded Coverage Options
• Positive Sentiment: CVS Health expanded its collaboration with Salesforce to streamline call center interactions using AI, which could improve service quality and operating efficiency across its member and provider base. CVS Health to Deliver Faster, More Personalized Call Center Care for Millions of Members with Salesforce's Agentforce Health
• Positive Sentiment: CVS Health also launched Aetna Mental Health On Demand and continued building out digital health capabilities, reinforcing its integrated care strategy. CVS Health Expands Integrated Care With Virtual Mental Health AI And GLP 1
• Neutral Sentiment: CVS received a Newsweek AI Impact Award for prescription-interpretation technology, highlighting innovation in pharmacy workflow and medication safety. CVS Health recognized for technology that improves medication safety and patient care
• Neutral Sentiment: Glenview Capital said CVS remains one of its top holdings, which supports investor confidence but does not by itself change fundamentals. Glenview Capital Keeps CVS Health (CVS) Among Top Holdings

Analysts Set New Price Targets

Several equities research analysts have issued reports on CVS shares. DA Davidson boosted their price objective on shares of CVS Health from $80.00 to $100.00 and gave the stock a "buy" rating in a research note on Thursday, May 7th. The Goldman Sachs Group boosted their price objective on shares of CVS Health from $95.00 to $97.00 and gave the stock a "buy" rating in a research note on Thursday, February 12th. Barclays boosted their price objective on shares of CVS Health from $101.00 to $106.00 and gave the stock an "overweight" rating in a research note on Tuesday. Mizuho boosted their price objective on shares of CVS Health from $102.00 to $110.00 and gave the stock an "outperform" rating in a research note on Wednesday, May 20th. Finally, Leerink Partners reiterated an "outperform" rating and set a $98.00 price objective on shares of CVS Health in a research note on Thursday, March 5th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $98.88.

CVS Health Stock Down 2.2%

CVS Health stock opened at $90.97 on Friday. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The company's 50-day moving average price is $82.07 and its two-hundred day moving average price is $79.55. The stock has a market cap of $116.06 billion, a price-to-earnings ratio of 40.07, a PEG ratio of 0.91 and a beta of 0.60.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The company had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same quarter last year, the firm posted $2.25 EPS. The business's revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts expect that CVS Health Corporation will post 7.44 EPS for the current fiscal year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd were given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend was Thursday, April 23rd. CVS Health's dividend payout ratio is 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.